The Patent Finder

ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof

BioAtla Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application PCT/US2019/058066, filed Oct 25, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 11,542,332ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof
In force
 · High confidence
BioAtla, Inc.In force
High confidence
US 12,649,793ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof
In force
 · Low confidence
BioAtla, Inc.In force
Low confidence
Application 19/666,809ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof
Pending
Not granted
BioAtla, Inc.PendingNot granted
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by BioAtla Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited